Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Bullboard Posts
Comment by pool1212on Apr 25, 2014 1:41pm
195 Views
Post# 22491847

RE:May 5th coming soon, Florida nice this time of year

RE:May 5th coming soon, Florida nice this time of year
Keep in mind the objective of ARVO conference for ICO Therapeutics is one of a poster presentation (information session), not a presentation of pure results of  different clinical phase results; therefore the delay has nothing to do with ARVO. Perhaps ARVO will become a stepping stone for the results and catalyst for the next step (upward we can only hope for).
Am also frustruated with current SP positon and like Jefferson have been invested and have continued to increase my position over the long haul. I would not be surprised to see sellers and speculators push down to 0.26-0.27 cents but that is by no means a reflection of the products ICO has invested in for development nor its mgmt team. The market and in particular the Vancouver exchange will have veery negative affects on listed companies who delay or miss forecasts, strictly due to the structure. 
JDRF, ISIS and others have backed ICO up until this point. Whether the results are good or bad at this point investing emotionally would be the worst case scenario. Might make sense to simply ignore, if possible what is happening for a few weeks and then see where we are. (for those who want to put me on ignore go ahead)

Good Luck

pool

Bullboard Posts